Adocia
Research Adocia (ADOC) on Bullrun: market cap EUR 81.23M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerADOC
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 81.23M
- Financial periodFY2025
- RevenueEUR 1.48M
- Revenue growth-84.2%
- Net income-EUR 16.59M
Valuation Snapshot
latest market cap is EUR 81.23M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 1.48M | -EUR 16.59M | n/a | n/a | -0.9 | EUR 17.25M | n/a | EUR 1.49M |
| FY2024 | EUR 9.32M | -EUR 9.32M | -EUR 15.84M | 88.0% | -1 | EUR 7.53M | EUR 11.83M | -EUR 3.09M |
| FY2023 | EUR 2.15M | -EUR 21.16M | -EUR 5.11M | 64.4% | -1.9 | EUR 12.96M | EUR 13.09M | -EUR 6.91M |
| FY2022 | EUR 11.45M | -EUR 6.90M | -EUR 15.15M | 83.9% | -0.9 | EUR 17.42M | EUR 33.21M | -EUR 12.97M |
| FY2021 | EUR 1.44M | -EUR 22.75M | -EUR 19.60M | 12.5% | -3.2 | EUR 15.16M | EUR 34.48M | -EUR 13.82M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 81.23M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Adocia
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Adocia's market cap?
Adocia's market capitalization is EUR 81.23M.
What does Adocia do?
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of pramlintide and lispro, as well as M1Pram, a combination of insulin M1 and pramlintide.